Advertisement

Preparation of Epidermal Growth Factor Conjugates Aimed for Boron Neutron Capture Therapy

  • Lars Gedda
  • Pär Olsson
  • Jörgen Carlsson

Abstract

Certain tumour cells, such as gliomas, melanomas and squamous carcinomas has increased numbers of epidermal growth factor receptors per cell, due to gene amplification or increased transcription rates1–3. These receptors could be used as targets for therapy with epidermal growth factor, EGF, conjugated with toxic agents. The numbers of receptors in normal cells are ranging from 0 to 104, but in the mentioned tumour cells the number can be highly increased. Growth factors carrying toxic agents could, due to its size, be better than antibodies at penetrating tumour tissues. The toxic agents could be radioactive nuclides, stable nuclides suitable for neutron capture or toxins. EGF, consisting only a 53 amino acid sequence and a molecular weight of about 6 kDa, has a compact and very stable structure. In earlier studies EGF has been modified without destruction of its biological activity or specificity to the receptor4–6.

Keywords

Boron Atom Toxic Agent Boron Neutron Capture Therapy Allyl Bromide Coupling Buffer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S.H. Bigner, P.C. Burger, A.J. Wong, M.H. Werner, S.R. Hamilton, L.H. Muilbaier, B. Vogelstein, and D.D. Bigner. Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J. Neuropath exp. Neurol. 47: 191–205, 1988.PubMedCrossRefGoogle Scholar
  2. 2.
    J. Mendelsohn. Growth factor receptors as targets for anti-tumour therapy with monoclonal antibodies. Monoclonal antibody therapy 45: 147–160, 1988.Google Scholar
  3. 3.
    V.P. Collins, and C.D. James. Gene and chromosomal alterations associated with the development of human gliomas. F4SEB J. 7: 926–930, 1993.Google Scholar
  4. 4.
    D.B. Cawley, H.R. Herschman, D.G. Gilliand, and R.J. Collier. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphteria fragment A is nontoxic. Cell. 22: 563–570, 1980.PubMedCrossRefGoogle Scholar
  5. 5.
    A. Andersson, A. Holmberg, J. Carlsson, J. Carlsson, J. Pontén, and B. Westermark. Binding of epidermal growth factor-dextran conjugates to cultured glioma cells. Int. J. Cancer. 47: 439–444, 1991.PubMedCrossRefGoogle Scholar
  6. 6.
    P. Olsson, A. Lindström, and J. Carlsson. Internalization and excretion of epidermal growth factor-dextran-associated radioactivity in cultured human squamous-carcinoma cells. Int. J. Cancer: 56: 529–537, 1994.PubMedCrossRefGoogle Scholar
  7. 7.
    B. Westermark, A. Magnusson, and C-H. Heldin. Effect of epidermal growth factor on membrane motility and cell locomotion in cultures or human clonal glioma cells. J. tn Neuro.science research. 8: 491–507, 1982.CrossRefGoogle Scholar
  8. 8.
    J. Carlsson, H. Drevin, and R. Axcn. Protein thiolation and reversible protein-protein conjugation. Biochem. J. 173: 723–737, 1978.PubMedGoogle Scholar
  9. 9.
    A. Holmberg, and L. Meurling. Preparation of sulfhydrylborane-dextran conjugates for boron neutron capture therapy. Bioconfugate chemistry 4: 570–573, 1993.CrossRefGoogle Scholar
  10. 10.
    P. Lindström, P. Olsson, J. Malmqvist, J. Pettersson, P. Lemmen, B. Werner, S. Sjöberg, A. Olin, and J. Carlsson. New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-I and B-Et-I 1-OMe in cultured human glioma and mouse melanoma cells. Anti-Cancer Drugs 5: 43–52, 1994.PubMedCrossRefGoogle Scholar
  11. 11.
    T. Hartman, and J. Carlsson. Radiation dose heterogeneous in receptor and antigen mediated boron neutron capture therapy. Radiotherapy and Oncology 31: 61–75, 1994.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Lars Gedda
    • 1
  • Pär Olsson
    • 1
  • Jörgen Carlsson
    • 1
  1. 1.Department of Radiation Sciences Division of Biomedical Radiation SciencesUppsala UniversityUppsalaSweden

Personalised recommendations